<--- Back to Details
First PageDocument Content
Eye / Clinical pharmacology / Medical prescription / Patient safety / Vitreomacular adhesion / Macular hole / Macular degeneration / Macula of retina
Date: 2015-07-10 08:30:48
Eye
Clinical pharmacology
Medical prescription
Patient safety
Vitreomacular adhesion
Macular hole
Macular degeneration
Macula of retina

SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) ® JETREA ocriplasmin 2.5 mg/ml Pharmaceutical Services Department of Health and Community Services

Add to Reading List

Source URL: www.health.gov.nl.ca

Download Document from Source Website

File Size: 174,24 KB

Share Document on Facebook

Similar Documents

Strictly embargoed for 00.01hrs, Friday 20 November  New target for macular degeneration gets funding for clinical trials The Medical Research Council is to fund researchers at the UCL Institute of Ophthalmology and Moor

Strictly embargoed for 00.01hrs, Friday 20 November New target for macular degeneration gets funding for clinical trials The Medical Research Council is to fund researchers at the UCL Institute of Ophthalmology and Moor

DocID: 1tWX0 - View Document

November 25, 2015 Foundation for Biomedical Research and Innovation RIKEN Kobe City Medical Center General Hospital Termination of subject enrollment for the “Clinical study of autologous induced pluripotent stem cell-

November 25, 2015 Foundation for Biomedical Research and Innovation RIKEN Kobe City Medical Center General Hospital Termination of subject enrollment for the “Clinical study of autologous induced pluripotent stem cell-

DocID: 1rstZ - View Document

What is OCT and what can you do with OCT? Introduction For most people, the severe vision loss of visual acuity or blindness are the worst imaginable fate that often more feared than cancer or death. But for most patient

What is OCT and what can you do with OCT? Introduction For most people, the severe vision loss of visual acuity or blindness are the worst imaginable fate that often more feared than cancer or death. But for most patient

DocID: 1rmdW - View Document

October 9, 2015 (Initially issued in Japanese on October 2, 2015) Foundation for Biomedical Research and Innovation (FBRI) RIKEN Kobe City Medical Center General Hospital Update on first transplant recipient in the “Cl

October 9, 2015 (Initially issued in Japanese on October 2, 2015) Foundation for Biomedical Research and Innovation (FBRI) RIKEN Kobe City Medical Center General Hospital Update on first transplant recipient in the “Cl

DocID: 1rm8x - View Document

2016 Pathways to Cures: Clinical Translational Research Day at UCI ORAL PRESENTATIONS 4:00 pm – 5:00 pm Pacific Ballroom D Session moderated by Dr. Michael Stamos

2016 Pathways to Cures: Clinical Translational Research Day at UCI ORAL PRESENTATIONS 4:00 pm – 5:00 pm Pacific Ballroom D Session moderated by Dr. Michael Stamos

DocID: 1r4Al - View Document